Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm

May 8, 2026 updated by: Université Catholique de Louvain

The goal of this observational study is to learn how the immune system responds to myeloproliferative neoplasms (MPN) in adults with known or suspected MPN. Researchers also want to identify immune cells that could help develop future immune-based treatments for MPN.

The main questions it aims to answer are:

  • Are there T cells in the bone marrow that can recognize MPN cells?
  • Which targets (antigens) on MPN cells are recognized by these immune cells?
  • Can researchers identify T cell receptors (TCRs) that may be used in future TCR-based therapies?

Researchers will study samples from adults with polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), post-PMF, or unclassifiable MPN. Samples from healthy donors without blood disorders will also be included for comparison.

By providing blood and bone marrow samples, participants will:

  • Allow researchers to study immune cells and genetic material from these samples
  • Allow researchers to perform laboratory tests to study how immune cells recognize MPN cells

Researchers will use laboratory methods such as genetic sequencing, cell analysis, and cell culture experiments to better understand immune responses in MPN.

Participants will not receive direct medical benefit from this study. The results may help researchers better understand MPN and support the future development of immune-based therapies.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Belgium
    • Woluwe
      • Brussels, Woluwe, Belgium, 1200
        • Recruiting
        • de Duve Institute, UCLouvain
        • Contact:
        • Principal Investigator:
          • Violaine Havelange

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

(i) Adult patients previously diagnosed with or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN.

(ii) Healthy controls undergoing hip replacement surgery, that have not been diagnosed with any hematological disease.

Description

Inclusion Criteria:

  • Patients previously diagnosed or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN.
  • Patients not previously diagnosed with a haematological disease as controls

Exclusion Criteria:

  • Patients with any other hematological malignancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Identification of MPN-specific CD8+ T cell clonotypes and corresponding tumor antigens
Time Frame: Throughout the whole study, approximately during 10 years
Throughout the whole study, approximately during 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Université Catholique de Louvain

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

December 1, 2036

Study Completion (Estimated)

January 1, 2037

Study Registration Dates

First Submitted

May 8, 2026

First Submitted That Met QC Criteria

May 8, 2026

First Posted (Actual)

May 15, 2026

Study Record Updates

Last Update Posted (Actual)

May 15, 2026

Last Update Submitted That Met QC Criteria

May 8, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MPN-TCR

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary Myelofibrosis (PMF)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe